Skip to main content

Table 1 Inclusion and exclusion criteria

From: Single-dose versus 3-day cotrimoxazole prophylaxis in transurethral resection or greenlight laser vaporisation of the prostate: study protocol for a multicentre randomised placebo controlled non-inferiority trial (CITrUS trial)

Inclusion criteria

Exclusion criteria

• Adult male patients (≥18 years)

• Obstructive voiding disorder (e.g. benign prostate hyperplasia, obstructive prostate cancer)

• Planned TURP or GL

• Evidence for (catheter-associated) UTI, with or without antibiotic treatment in the last 7 days prior to randomisation

• Any evidence of a history of positive urine culture (cfu ≥ 105/ml in midstream urine with no more than two species) and resistance to TMP/SMX in the last 7 days prior to randomisation [24]

• Known contraindication against study drugs according to the Swissmedic package leaflet (e.g. patients with known liver dysfunction, renal insufficiency or glomerular filtration rate (calculated by the MDRD or CKD-EPI) < 30 ml/min or dialysis patients will be excluded)

• Antibiotic treatment for any reason within 7 days prior to randomisation

• Indication for AP for other reasons (e.g. endocarditis prophylaxis, transplanted patients under systemic immunosuppression)

  1. AP antimicrobial prophylaxis, cfu colony forming units, CKD-EPI Chronic Kidney Disease Epidemiology Collaboration, GL Greenlight laser vaporisation, MDRD Modification of Diet in Renal Disease, TMP/SMX trimethoprim/sulfamethoxazole (cotrimoxazole), TURP Transurethral resection of the prostate, UTI urinary tract infection
Back to article page

Trials

ISSN: 1745-6215